ArticleGynecologic oncology reports2026
Fertility desires and outcomes in patients with selected hereditary cancer syndromes.
Article in Gynecologic oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Limited data exist on pregnancy desires, outcomes, or referral rates in patients with gynecologic hereditary cancer syndromes. This study describes fertility desires and pregnancy outcomes in patients with newly diagnosed BRCA1, BRCA2, MLH1, and MSH2 mutations. Methods: This was a multi-site, retrospective cohort study including women aged 21-45 years old diagnosed with a pathogenic variant in BRCA1, BRCA2, MLH1, or MSH2 between January 2018 and December 2021. Women with prior sterilization procedures, bilateral salpingectomy, hysterectomy, or prior diagnosis of breast or ovarian cancer were excluded. Clinical and demographic variables were extracted from the medical record. The primary outcome was assessment of pregnancy desires. Secondary outcomes included rate of pregnancy and live birth, referral to REI or use of assisted reproductive technology (ART). Results: We identified 396 patients with positive genetic testing during the study period. BRCA2 (n = 200, 51%) and BRCA1 (n = 173, 44%) mutations were the most common. Median age at diagnosis was 31.5 (27-38) years old with most women being non-Hispanic white (53.2%) and nulliparous (n = 216, 55%). In the cohort, 38.1% of women desired future fertility at the time of diagnosis, 31.3% had completed childbearing, and fertility desires were not documented in 30.6%. There were 65 pregnancies. Parity and age 25-34 years was associated with achieving pregnancy. Even in patients desiring future fertility, rates of referral to REI (17%) and use of ART (8%) were low. Conclusion: Our findings demonstrate possible gaps in counseling and underutilization of fertility services for young mutation carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.